- Clinical development services group Hvivo said a trial of its mild to moderate influenza drug had met its primary objective, and would enter the next phase of testing.

One dose of FLU-v produced a 'highly statistically significant' reduction in the primary endpoint of Mild to Moderate Influenza Disease, comprising a 'positive signal of influenza infection and at least one influenza symptom, compared with placebo,' the company said.

FLU-v was being developed by Imutex, hVIVO's 49% joint venture with the Seek Group.

'These final results are further verification that FLU-v is achieving measures of clinical efficacy and is now positioned to enter Phase III. The successful achievement of statistical significance in the primary endpoints from two Phase II studies confirms that FLU-v has clinical impact in establishing immunity and disease, symptom and viral load reduction,' the company said.

'The exploratory design of -004 has also enabled us to determine, what we believe to be the most appropriate clinical efficacy endpoint, relating to confirmed influenza infection, for application in the Phase III programme and we look forward to discussing this with the regulatory authorities at our next meetings.'

At 10:22am: [LON:HVO] hVIVO Plc share price was +3.5p at 32p

Story provided by